Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name 4r,6r-dorzolamide
Drug ID BADD_D00006
Description Dorzolamide is a non-bacteriostatic sulfonamide derivative [A1304] and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension.[L11377] It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes.[A1303] Unlike oral CA inhibitors, dorzolamide has negligible effects of acid-base or electrolyte disturbances and other systemic adverse effects.[A1304] First marketed in 1995,[A190624] dorzolamide is available in ophthalmic solutions as monotherapy marketed as Trusopt [L11377] or in combination with [timolol] as Cosopt PF.[L11380]
Indications and Usage For the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Also used prophylatically for the inhibition of perioperative IOP increase (before neodynium yttrium aluminum garnet laser posterior capsulotomy).
Marketing Status Prescription; Discontinued
ATC Code S01EC03
DrugBank ID DB00869
KEGG ID D07871
MeSH ID C062765
PubChem ID 92087
TTD Drug ID D05UYW
NDC Product Code 14445-404; 70377-081
Synonyms dorzolamide | 4-ethylamino-5,6-dihydro-6-methyl-7,7-dioxide-4H-thieno(2,3-b)thiopyran-2-sulfonamide | 5,6-dihydro-4-ethylamino-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide | dorzolamide, (trans)-isomer | Dorzolamide Chibret | MK 507 | MK-507 | Trusopt | dorzolamide hydrochloride | L 671152 | L-671,152
Chemical Information
Molecular Formula C10H16N2O4S3
CAS Registry Number 120279-89-2
SMILES CCNC1CC(S(=O)(=O)C2=C1C=C(S2)S(=O)(=O)N)C
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nervousness19.06.02.003--Not Available
Nightmare19.02.03.003--Not Available
Oedema08.01.07.006; 14.05.06.010--Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Palpitations02.01.02.003--
Paraesthesia17.02.06.005--
Peripheral coldness08.01.09.010; 24.04.03.006--Not Available
Peyronie's disease21.12.01.002--Not Available
Pharyngitis07.05.07.004; 11.01.13.003; 22.07.03.004--
Photophobia06.01.01.004; 17.17.02.006--
Pruritus23.03.12.001--
Psoriasis10.02.01.036; 23.03.14.002--Not Available
Pulmonary oedema02.05.02.003; 22.01.03.003--
Punctate keratitis06.04.02.003--Not Available
Rales22.02.04.004--Not Available
Rash23.03.13.001--Not Available
Rash erythematous23.03.06.003--Not Available
Rash generalised23.03.13.002--Not Available
Respiratory distress22.02.01.012--Not Available
Respiratory failure14.01.04.003; 22.02.06.002--
Retroperitoneal fibrosis07.07.03.003; 10.02.01.026; 20.06.01.006--Not Available
Scab23.03.03.004--Not Available
Shock24.06.02.002--Not Available
Sinoatrial block02.03.01.010--Not Available
Sinusitis11.01.13.005; 22.07.03.007--
Skin irritation23.03.04.009--Not Available
Somnolence17.02.04.006; 19.02.05.003--
Stevens-Johnson syndrome10.01.03.020; 11.07.01.005; 12.03.01.014; 23.03.01.007--
Strangury20.02.02.017--Not Available
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages